News & Events

Randall D. Wolcott, M.D., C.W.S.

President, Randall D. Wolcott MD Professional Association
and Research and Testing Lab of the South Plains
Lubbock, Texas

Dr. Wolcott received his BS from Bethany Nazarene College in Bethany, Oklahoma in 1977 and his MD from the University of Oklahoma in 1981. He is currently an Adjunct Professor, Department of Microbiology and Immunology at Texas Tech University Health Sciences Center in Lubbock, Texas. He is also a Medical Advisor for the Phage Therapy Center in Tbilisi, the Democratic Republic of Georgia, and Medical Director of Southwest Regional Wound Care Center in Lubbock, Texas.

Some of Dr. Wolcott’s present credentials include: Founding Member of the BioTherapeutics Education & Research Foundation; member of the Association of the Advancement of Wound Care; Board Certified American Academy of Wound Management; Board Certified American Board of Physical Medicine and Rehabilitation; and Board Certified American Association of Neuromuscular & Electrodiagnostic Medicine.

About the lecture

"Current Use of Bacteriophage in Clinical Medicine"

Bacteriophages are the most common biological entity on the planet. Since their discovery about a century ago, scientists and clinicians have been trying to harness their natural killing power to control microbial infections. The discovery of antibiotics overshadowed the potential of phage therapy for decades, but the surge in antibiotic-resistant bacteria and the understanding of bacterial biofilm infections have reignited Western interest in phage therapy. Phage therapy has been practiced in some areas of the world, largely uninterrupted, for decades. These treatments centers are effective, but it is difficult to translate the practices of these clinics and laboratories to the West. Only recently, have double-blinded phage therapy trials been conducted, and efforts are being made to Westernize phage therapy practices by formulating static cocktails and isolating single phage components that may have therapeutic value.

The value of phages is their ability to evolve with their hosts, but the ability for phages to overcome host resistances may be curtailed by Western regulatory practices. It is important to understand the complexity of chronic bacterial infections, so the phage therapy can be rationally implemented.

Quoted from the 2008-2009 Philip C. and Ethel F. Ashby Lecture Announcement Announcement Brochure